Literature DB >> 26259966

Impact of Attention-Deficit Hyperactivity Disorder on School Performance: What are the Effects of Medication?

Raman Baweja1, Richard E Mattison2, James G Waxmonsky2.   

Abstract

Attention-deficit hyperactivity disorder (ADHD) affects an estimated 5-7 % of schoolchildren worldwide. School functioning and academic achievement are frequently impaired by ADHD and represent one of the main reasons children start ADHD medication. Multiple potential causal pathways exist between ADHD and impaired school performance. In this review, we decompose school performance into three components and assess the impact of ADHD and its treatments on academic performance (assessed by grade point average [GPA], time on-task, percentage of work completed as well as percent completed correctly), academic skills (as measured by achievement tests and cognitive measures), and academic enablers (such as study skills, motivation, engagement, classroom behavior and interpersonal skills). Most studies examined only the short-term effects of medication on school performance. In these, ADHD medications have been observed to improve some aspects of school performance, with the largest impact on measures of academic performance such as seatwork productivity and on-task performance. In a subset of children, these benefits may translate into detectable improvements in GPA and achievement testing. However, limited data exists to support whether these changes are sustained over years. Optimizing medication effects requires periodic reassessment of school performance, necessitating a collaborative effort involving patients, parents, school staff and prescribers. Even with systematic reassessment, behavioral-based treatments and additional school-based services may be needed to maximize academic performance for the many youth with ADHD and prominent impairments in school performance.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26259966     DOI: 10.1007/s40272-015-0144-2

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN: 1174-5878            Impact factor:   3.022


  120 in total

1.  Effects of atomoxetine with and without behavior therapy on the school and home functioning of children with attention-deficit/hyperactivity disorder.

Authors:  James G Waxmonsky; Daniel A Waschbusch; William E Pelham; Lillian Draganac-Cardona; Bryan Rotella; Lynn Ryan
Journal:  J Clin Psychiatry       Date:  2010-06-29       Impact factor: 4.384

2.  Implications of changes for the field: ADHD.

Authors:  Margaret H Sibley; James G Waxmonsky; Jessica A Robb; William E Pelham
Journal:  J Learn Disabil       Date:  2012-11-05

3.  Efficacy and safety of dexmethylphenidate extended-release capsules in children with attention-deficit/hyperactivity disorder.

Authors:  Laurence L Greenhill; Rafael Muniz; Roberta R Ball; Alan Levine; Linda Pestreich; Hai Jiang
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-07       Impact factor: 8.829

4.  Placebo-controlled evaluation of amphetamine mixture-dextroamphetamine salts and amphetamine salts (Adderall): efficacy rate and side effects.

Authors:  P A Ahmann; F W Theye; R Berg; A J Linquist; A J Van Erem; L R Campbell
Journal:  Pediatrics       Date:  2001-01       Impact factor: 7.124

5.  Characteristics of Norwegian children suffering from ADHD symptoms: ADHD and primary health care.

Authors:  Nezla S Duric; Irene Elgen
Journal:  Psychiatry Res       Date:  2011-05-31       Impact factor: 3.222

6.  Efficacy of two long-acting methylphenidate formulations in children with attention- deficit/hyperactivity disorder in a laboratory classroom setting.

Authors:  Raul Silva; Rafael Muniz; Linda K Pestreich; Matthew Brams; Ann Childress; Frank A Lopez
Journal:  J Child Adolesc Psychopharmacol       Date:  2005-08       Impact factor: 2.576

7.  Assessing Homework Problems in Children with ADHD: Validation of a Parent-Report Measure and Evaluation of Homework Performance Patterns.

Authors:  Joshua M Langberg; L Eugene Arnold; Amanda M Flowers; Mekibib Altaye; Jeff N Epstein; Brooke S G Molina
Journal:  School Ment Health       Date:  2010-03-01

8.  Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status.

Authors:  S Mannuzza; R G Klein; A Bessler; P Malloy; M LaPadula
Journal:  Arch Gen Psychiatry       Date:  1993-07

9.  Academic achievement over 8 years among children who met modified criteria for attention-deficit/hyperactivity disorder at 4-6 years of age.

Authors:  Greta M Massetti; Benjamin B Lahey; William E Pelham; Jan Loney; Ashley Ehrhardt; Steve S Lee; Heidi Kipp
Journal:  J Abnorm Child Psychol       Date:  2007-10-17

10.  Long-Term Outcomes of ADHD: Academic Achievement and Performance.

Authors:  L Eugene Arnold; Paul Hodgkins; Jennifer Kahle; Manisha Madhoo; Geoff Kewley
Journal:  J Atten Disord       Date:  2015-01-12       Impact factor: 3.256

View more
  16 in total

1.  Attention-Deficit/Hyperactivity Disorder, School Performance, and Effect of Medication.

Authors:  Andreas Jangmo; Amanda Stålhandske; Zheng Chang; Qi Chen; Catarina Almqvist; Inna Feldman; Cynthia M Bulik; Paul Lichtenstein; Brian D'Onofrio; Ralf Kuja-Halkola; Henrik Larsson
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-02-02       Impact factor: 8.829

2.  Association Between Medication Use and Performance on Higher Education Entrance Tests in Individuals With Attention-Deficit/Hyperactivity Disorder.

Authors:  Yi Lu; Arvid Sjölander; Martin Cederlöf; Brian M D'Onofrio; Catarina Almqvist; Henrik Larsson; Paul Lichtenstein
Journal:  JAMA Psychiatry       Date:  2017-08-01       Impact factor: 21.596

3.  Quality of life, adjustment, and associative comorbid conditions in children diagnosed with attention deficit hyperactivity disorder: A comparative study.

Authors:  Krishan Kumar; Rajni Sharma; Aseem Mehra; Lokesh Saini; Ruchita Shah; Akhilesh Sharma
Journal:  Ind Psychiatry J       Date:  2020-11-07

4.  The effect of stimulant medication on the learning of academic curricula in children with ADHD: A randomized crossover study.

Authors:  William E Pelham; Amy R Altszuler; Brittany M Merrill; Joseph S Raiker; Fiona L Macphee; Marcela Ramos; Elizabeth M Gnagy; Andrew R Greiner; Erika K Coles; Carol M Connor; Christopher J Lonigan; Lisa Burger; Anne S Morrow; Xin Zhao; James M Swanson; James G Waxmonsky; William E Pelham
Journal:  J Consult Clin Psychol       Date:  2022-05

5.  Gray Matter Network Associated With Attention in Children With Attention Deficit Hyperactivity Disorder.

Authors:  Xing-Ke Wang; Xiu-Qin Wang; Xue Yang; Li-Xia Yuan
Journal:  Front Psychiatry       Date:  2022-07-04       Impact factor: 5.435

6.  Identification of Genetic Loci Shared Between Attention-Deficit/Hyperactivity Disorder, Intelligence, and Educational Attainment.

Authors:  Kevin S O'Connell; Alexey Shadrin; Olav B Smeland; Shahram Bahrami; Oleksandr Frei; Francesco Bettella; Florian Krull; Chun C Fan; Ragna B Askeland; Gun Peggy S Knudsen; Anne Halmøy; Nils Eiel Steen; Torill Ueland; G Bragi Walters; Katrín Davíðsdóttir; Gyða S Haraldsdóttir; Ólafur Ó Guðmundsson; Hreinn Stefánsson; Ted Reichborn-Kjennerud; Jan Haavik; Anders M Dale; Kári Stefánsson; Srdjan Djurovic; Ole A Andreassen
Journal:  Biol Psychiatry       Date:  2019-11-29       Impact factor: 13.382

7.  Low-Resolution Electromagnetic Tomography (LORETA) of changed Brain Function Provoked by Pro-Dopamine Regulator (KB220z) in one Adult ADHD case.

Authors:  Bruce Steinberg; Kenneth Blum; Thomas McLaughlin; Joel Lubar; Marcelo Febo; Eric R Braverman; Rajendra D Badgaiyan
Journal:  Open J Clin Med Case Rep       Date:  2016

8.  Medical treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and children's academic performance.

Authors:  Maria Keilow; Anders Holm; Peter Fallesen
Journal:  PLoS One       Date:  2018-11-29       Impact factor: 3.240

9.  A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD.

Authors:  Azmi Nasser; Tesfaye Liranso; Toyin Adewole; Nicholas Fry; Joseph T Hull; Fatima Chowdhry; Gregory D Busse; Zare Melyan; Andrew J Cutler; Robert L Findling; Stefan Schwabe
Journal:  Psychopharmacol Bull       Date:  2021-03-16

10.  A Phase 3, Placebo-Controlled Trial of Once-Daily Viloxazine Extended-Release Capsules in Adolescents With Attention-Deficit/Hyperactivity Disorder.

Authors:  Azmi Nasser; Tesfaye Liranso; Toyin Adewole; Nicholas Fry; Joseph T Hull; Gregory D Busse; Fatima Chowdhry; Andrew J Cutler; Nandita Joshi Jones; Robert L Findling; Stefan Schwabe
Journal:  J Clin Psychopharmacol       Date:  2021 Jul-Aug 01       Impact factor: 3.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.